CIK 0001601485 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Elicio Therapeutics, Inc.
Sign in to watch- Ticker
- ELTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113430072
- Phone
- (857) 209-0050
- Business address
- 451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
- Former names
- Angion Biomedica Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-28 | Chudnovsky Yekaterina Director | Purchase · Common Warrants | +1,600,000 | 1,600,000 | ||
| 2024-06-28 | Chudnovsky Yekaterina Director | Purchase · Pre-Funded Warrants | +1,600,000 | $4.99 | $8.0M | 1,600,000 |
| 2024-03-19 | Chudnovsky Yekaterina Director | Purchase · Pre-Funded Common Stock Purchase Warrant | +1,032,702 | $5.81 | $6.0M | 1,032,702 |
| 2024-02-01 | Piekos Brian Chief Financial Officer | Grant or award · Stock Option (right to buy) | +43,225 | 43,225 | ||
| 2024-02-01 | Connelly Robert CEO, President and Director | Grant or award · Stock Option (right to buy) | +225,137 | 225,137 | ||
| 2024-02-01 | Haqq Christopher See Remarks | Grant or award · Stock Option (right to buy) | +28,200 | 28,200 | ||
| 2024-02-01 | DeMuth Peter Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +29,800 | 29,800 | ||
| 2024-02-01 | DeMuth Peter Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +342 | 342 | ||
| 2023-12-28 | Nissenson Allen Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | Chudnovsky Yekaterina Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | WILSON KAREN J Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | Ashe Carol Gail Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | Venkatesan Jay Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | ADAMS JULIAN Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-28 | RUFFOLO ROBERT R Director | Grant or award · Stock Option (right to buy) | +4,100 | 4,100 | ||
| 2023-12-22 | Chudnovsky Yekaterina Director | Purchase | +1,213,000 | $5.81 | $7.0M | 1,915,639 |
| 2023-06-01 | Piekos Brian Chief Financial Officer | Grant or award · Stock Option (right to buy) | +75,484 | 75,484 | ||
| 2022-07-01 | Goldberg Itzhak Director | Shares withheld for taxes | −32,082 | $1.12 | $36K | 1,687,986 |
| 2022-06-09 | GANZI VICTOR F Director | Grant or award · Common Stock | +15,000 | 15,000 | ||
| 2022-06-09 | Nissenson Allen Director | Grant or award · Common Stock | +15,000 | 15,000 |
Page 4 of 9 · 171 trades